87/100 A · Moderate risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

ALCHIMEDICS

Active 5710 7219 Active for 19 years

5710 · RC 492933262 · Active since 2006

A

Overview

ALCHIMEDICS is a 5710 registered , France, since 2006. The company operates in the 7219 sector. With reported revenue of 518K EUR in 2018. Its TraceComp score of 87 (A) indicates solid fundamentals and low apparent risk. With 19 years of operations, the company has an established track record in its market.

Company Information

Registration Number
492933262
Legal Form
5710
Registered
2006-11-17

Financial Profile

Latest filed accounts: FY 2018 · most recent available in public filings

Revenue (2018) 517,564 EUR
Net Income 273,532 EUR
Total Assets 705,326 EUR
Altman Z 1.62 grey

Multi-year financials & ratios

4 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

3 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
CHRISTOPHE BUREAU role 73 Current
+ 2 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Patent Portfolio

Active patent holder. 7 patents · 7 active · 7 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue up 6285% year-on-year
  • Profitable: positive net income in FY 2018

Data Sources & Freshness

Data sourced from: bulk register.